E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Depressive disorder requiring treatment with electroconvulsive treatment (ECT) |
|
E.1.1.1 | Medical condition in easily understood language |
Depression requiring treatment with electroconvulsive treatment (ECT) |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Mental Disorders [F03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10012378 |
E.1.2 | Term | Depression |
E.1.2 | System Organ Class | 10037175 - Psychiatric disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Ketamine vs saline treatment will reduce ECT-induced cognitive impairments as measured by being able to learn new verbal information (anterograde verbal memory), remember personal events from their past (autobiographical memory) and saying the names of objects fluently (verbal fluency) |
|
E.2.2 | Secondary objectives of the trial |
CLINICAL HYPOTHESES 1) Four months after ECT a significant difference between ketamine and saline groups in cognitive function will remain only for autobiographical memory 2). Ketamine vs saline treatment will result in a greater decrease in depression scores after 4 treatments 3) Compared with saline, patients receiving ketamine will need fewer ECT treatments to achieve remission MECHANISTIC HYPOTHESES 4) Ketamine vs saline, treatment will increase frontal cortex activation as measured by brain imaging (fNIRS and fMRI) in response to a verbal fluency, but not a working memory task, and this will relate to group differences in task performance. 5) Ketamine vs saline treatment will result in stronger frontal cortex-hippocampal connections (measured by functional connectivity analysis with fMRI with the verbal fluency task). 6) Ketamine treatment vs saline treatment will be associated with a relative increase in frontal brain blood oxygenation which will be related to differences |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patient Inclusion criteria: 1.Male or female aged 18 years and above; 2.Current DSM-IV diagnosis of a major depressive episode, moderate or severe as part of unipolar or bipolar disorder mood disorder diagnosed by the Mini International Neuropsychiatric Interview (MINI) 3.American Society of Anaesthesiologists (ASA) score (excluding mental health considerations in the scoring) of 1, 2 or stable 3, and judged as suitable to receive ketamine by an anaesthetist; 4.Verbal IQ ≥ 85, sufficiently fluent in English to validly complete neuropsychological testing; 5.Capacity to give informed consent; 6.Willing to undertake neuropsychological testing as part of the study. Healthy control inclusion criteria: 1.Aged 18 years or more; 2.Currently psychiatrically well, confirmed through MINI interview and no current psychotropic medication; 3.In good physical health. |
|
E.4 | Principal exclusion criteria |
Patient exclusion criteria: 1.DSM-IV diagnosis of a primary psychotic or schizoaffective disorder, current primary obsessive compulsive disorder or anorexia nervosa; 2.History of drug or alcohol dependence (DSM-IV criteria) within the last year; 3.ECT in last 6 months (to avoid confounding the assessment of cognitive outcomes) or has previously received ECT in the current trial; 4.Known hypersensitivity or contraindication to ketamine or excipients in the injection; including significant cardiovascular disease, uncontrolled hypertension, glaucoma, cirrhosis or significant liver impairment; 5.Known hypersensitivity or contraindication to concomitant medications used for ECT: thiopentone (thiopental), propofol and suxamethonium or excipients in the injections; 6.Evidence of organic brain disease including dementia, neurological illness or injury, or medical illness which may significantly affect neuropsychological function; 7.Detained under the Mental Health Act (1983 as amended 2007) or unable to give informed consent; 8.Pregnancy, or at risk of pregnancy and not taking adequate contraception, breastfeeding; 9.Score ≤ 24 on the Mini Mental State Examination (MMSE); 10.In the subgroup receiving MRI based investigation (fMRI, MRS and ASL) contraindication to MRI (eg metal implants or foreign bodies such as from a surgical implant, accident or injury). Control exclusion Criteria: 1.Personal history of psychiatric disorder, as revealed by MINI interview; 2.First degree family history of major psychiatric illness requiring treatment; 3.Significant physical illness including organic brain disease, neurological illness or injury that could interfere with interpretation of results; 4.Psychotropic medication or other medication that could interfere with interpretation of results; 5.Score ≤ 24 on the Mini Mental State Examination (MMSE); 6.In the subgroup receiving MRI based investigation (fMRI, MRS and ASL) contraindication to MRI (eg metal implants or foreign bodies such as from a surgical implant, accident or injury). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change in memory between baseline and end of ECT course measured by: Hopkins Verbal Learning Test – Revised (HVLT-R) Autobiographical Memory Interview - short form (AMI-SF) Controlled Oral Word Association Test (COWAT) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Changes between baseline and end of ECT course |
|
E.5.2 | Secondary end point(s) |
A Changes in memory between baseline and one and 4 month follow up measured by: Hopkins Verbal Learning Test – Revised (HVLT-R) Autobiographical Memory Interview - short form (AMI-SF) Controlled Oral Word Association Test (COWAT) B Cognitive changes between baseline and end of ECT, and one and 4 month follow up measured by: Medical College of Georgia Complex Figure Test (MCG complex figure test) Digit span Self-reported Global Self Evaluation of Memory (GSE-My) C Symptoms ratings measured from baseline to after 4 ECT treatments, at end of ECT and at one and 4 month follow up measured by: Mongomery Asberg Depression Rating Scale Clinical Anxiety Scale Brief Psychiatric Rating Scale Remission at end of ECT (MADRS ≤10) Number of ECT treatments to achieve remission Response at end of ECT (≥ 50% decrease in MADRS from baseline) Clinical Global Impression – Severity and Improvement (CGI-S, CGI-I) Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR) Proportion significantly worsening after end of ECT (MADRS increase of ≥4 points + CGI-S increase of ≥1 point to CGI-S ≥3 compared with assessment at end of ECT. D Mechanistic outcomes in subgroups between baseline and end of ECT, and at one and 4 month follow up: Haemodynamic response to verbal fluency and working memory tasks using fNIRS Tissue oxygenation index measured by NIRS E Mechanistic outcomes in subgroups between baseline and end of ECT: Haemodynamic response to verbal fluency and working memory tasks using fMRI Brain glutamate concentration measured by magnetic resonance spectroscopy Frontal blood flow measure by arterial spin labelling fMRI |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
A: Changes between baseline and one and 4 month follow up. B: Changes between baseline and end of ECT, and one and 4 month follow up. C and D: Baseline, after 4 ECT treatments, at end of ECT and at one and 4 month follow up. E: Baseline and end of ECT |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Mechanistic using brain imaging |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Anesthetist giving drug not blind, ECT/clinical team + assessors blind |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 29 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 29 |